New financing and clinical trial for RSV/hMOV bivalent vaccine
Drug Discovery World
SEPTEMBER 25, 2024
Vicebio has announced a $100 million Series B financing, which will be used to develop next-generation vaccines for respiratory viruses. The development will utilise Vicebio’s Molecular Clamp technology, discovered at The University of Queensland. There is currently no commercially available vaccine targeting RSV and hMPV.
Let's personalize your content